Navigation Links
Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
Date:12/19/2011

BUFFALO, N.Y., Dec. 19, 2011 /PRNewswire/ -- Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement from Hanmi Pharmaceuticals granting Kinex Pharmaceuticals exclusive rights to their Orascovery technology (which includes a non-absorbed compound that facilitates the absorption of compounds that are usually not orally bioavailable or absorbed) and their current lead products including an oral formulation of paclitaxel, which is already in Phase II clinical trials in Korea, and an oral formulation of irinotecan, which has just completed Phase I clinical trials in Korea.

The Orascovery program is one of the key platforms developed by Hanmi Pharmaceuticals. HM30181A is a P-glycoprotein pump inhibitor, (known for its effect in pumping drugs back to the gastrointestinal tract and thereby reducing drug absorption) which inhibits the pumping action of this protein and therefore, serves as an oral absorption enhancer. This compound is very potent and is largely not absorbed and therefore, exerts its effect mainly in the gastrointestinal tract.

In preclinical studies, it has been shown that the administration of this absorption enhancer together with paclitaxel enhances the oral bioavailability of paclitaxel from 1% to >40%. For irinotecan and topotecan, the oral bioavailabilities were shown to be enhanced from 8% and 11% to >40% and >50%, respectively. The composition of matter of HM30181A is covered by issued patents.

The acquisition of an oral formulation of paclitaxel is important to both Kinex and Hanmi Pharmaceuticals as the taxanes have been shown to exhibit a strong synergistic effect with KX01, an orally bioavailable dual src kinase/pretubulin inhibitor that Kinex Pharmaceuticals and Hanmi Pharmaceuticals have been collaborating to develop since April 2011.

Under the terms of the agreement, Kinex Pharmaceuticals will acquire the rights to the development and co
'/>"/>

SOURCE Kinex Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
2. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer
3. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
4. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
5. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
6. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
7. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
8. Valeant Pharmaceuticals Completes Acquisition of Dermik
9. Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc.s Board of Directors for Possible Breaches of Fiduciary Duty
10. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
11. Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), ... that the United States Patent and Trademark Office has ... patent application directed to the fundamental technology involved in ... delivery systems. The allowable subject matter is directed to ...
... Aug. 3, 2011 Reportlinker.com announces ... is available in its catalogue: ... and Services Market 2011-2021 - what ... http://www.reportlinker.com/p0578544/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021---what-are-the-revenue-prospects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ...
Cached Medicine Technology:Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 2Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 3Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 13
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... badly treated fractures are some of the reasons why ... often laid up, according to orthopaedic experts here. ... with many delicate and complicated surgeries being performed here ... at the All India Institute of Medical Sciences (AIIMS) ...
... eyes could reveal the status of our health and ... disease.// ,Conventional vision tests reveal eyesight abnormalities, such ... Rosen, of Rosen Eye Associates, Manchester, a test of ... heart disease, cancer and diabetes, thanks to its superior ...
... exposure to industrial chemicals is causing a ‘silent pandemic’ ... globe. ,This study was published on Tuesday ... 1-in-6 children and most of the cases are disorders ... that disorders like autism, attention deficit disorder, cerebral palsy ...
... advised to build a three-month stockpile of food, medicine and ... pandemic, a news report said Tuesday. ,An advisory ... in the former British colony urging them to prepare the ... ,It suggests stockpiling 4.5 litres of water per person per ...
... lower the risk of acquiring a sexually transmitted infection, ... ,The November issue of Pediatrics which reports ... of acquiring and spreading such infections by up to ... routine neonatal circumcision. ,This study is only ...
... getting heavier , but a new study by Statistics Canada has a ... pace as they did earlier. //Adults between 18-64 were monitored for ... showed that they have put on weight steadily , but during the ... ,This welcome news is thought to be due to the fact that ...
Cached Medicine News:Health News:Mismanagement of fractures a major concern, say experts 2Health News:Eye could reveal serious health disorder 2Health News:Brain disorders caused by Industrial chemicals 2Health News:Risk of STD Lowered with Circumcision 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: